Literature DB >> 16227164

Diagnostic delay in primary central nervous system lymphoma.

Ingfrid S Haldorsen1, Ansgar Espeland, John Ludvig Larsen, Olav Mella.   

Abstract

This study investigates delay in diagnosing primary central nervous system lymphoma (PCNSL), which has a variable clinical and radiological presentation. Early diagnosis and treatment may improve survival and cause less sequela in PCNSL. Medical records of all new cases of PCNSL morphologically verified while alive or by autopsy in Norway in 1989-1998 were reviewed (n = 74). The time from initial symptom to final morphological diagnosis of PCNSL had a median (mean, range) of 70 (106, 22-330) days in 16 AIDS patients and 75 (157, 8-1285) days in 58 non-AIDS patients. Among non-AIDS patients, the time to diagnosis was longer in patients with no tumour in the first neuroimaging report after initial symptom (p = 0.001). Median (mean, range) time from initial symptom to neuroimaging was 14 (25, 1-60) days in AIDS patients and 21 (88, 1-1095) days in non-AIDS patients. In the non-AIDS group, those presenting with personality change or visual disturbance had more delayed imaging than the others. The time from first neuroimaging examination to final diagnosis in non-AIDS patients had a median (mean, range) of 28 (69, 1-845) days, and was longer when no tumour was indicated in the imaging report (p = 0.005) and if first biopsy did not confirm the diagnosis (p = 0.02). All AIDS patients had their diagnosis of PCNSL first established by autopsy. The time from first neuroimaging to autopsy had a median (mean, range) of 48 (81, 10-270) days. There is a considerable delay in the diagnosis of PCNSL and strategies for earlier diagnosis are thus needed. Physicians should consider early neuroimaging in patients with personality changes or visual disturbance, early renewed imaging in patients with persistent neurological symptoms but no tumour on initial imaging, and early/repeated biopsy of focal brain lesions in both AIDS patients and non-AIDS patients.

Entities:  

Mesh:

Year:  2005        PMID: 16227164     DOI: 10.1080/02841860500256272

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  24 in total

1.  Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.

Authors:  R Mangla; B Kolar; T Zhu; J Zhong; J Almast; S Ekholm
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

2.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

3.  Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI.

Authors:  Fu-Hua Lin; Xiang-Heng Zhang; Ji Zhang; Zhen-Qiang He; Hao Duan; Chao Ke; Ke Sai; Xiao-Bing Jiang; Fuad Al-Nahari; Shao-Yan Xi; Yong-Gao Mou
Journal:  J Neurooncol       Date:  2018-08-16       Impact factor: 4.130

Review 4.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

5.  Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma.

Authors:  Thomas S Uldrick; Sharon Pipkin; Susan Scheer; Nancy A Hessol
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

6.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

7.  Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability.

Authors:  Evrim Önder; Ata T Arıkök; Sevgen Önder; Ünsal Han; Mehmet Sorar; Hayri Kertmen; Engin D Yılmaz; Ramazan Fesli; Murat Alper
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 8.  Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature.

Authors:  Cristina Izquierdo; Roser Velasco; Noemí Vidal; Juan José Sánchez; Andreas A Argyriou; Sarah Besora; Francesc Graus; Jordi Bruna
Journal:  Neuro Oncol       Date:  2015-09-27       Impact factor: 12.300

9.  Homonymous hemianopsia as the leading symptom of a tumor like demyelinating lesion: a case report.

Authors:  Maria Eleptheria Evangelopoulos; Dimitrios Stergios Evangelopoulos; Costas Potagas; Costantinos Sfagos
Journal:  Cases J       Date:  2009-12-21

10.  Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme.

Authors:  R Cerqua; S Balestrini; C Perozzi; V Cameriere; S Renzi; G Lagalla; G Mancini; M Montanari; P Leoni; M Scerrati; M Iacoangeli; M Silvestrini; S Luzzi; L Provinciali
Journal:  Neurol Sci       Date:  2015-08-02       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.